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Purpose: Cochlear implants are widely used for hearing rehabilitation of deaf children with 
congenital deafness or adults with acquired severe-to-profound hearing loss. The sound pro-
cessor antenna creates a radio frequency-electromagnetic field transmitting the sound signal 
to the implant, similar to that in a mobile phone. A recent case report suggested a relationship 
between cochlear implants and malignant glioma, and some epidemiological studies have sug-
gested an increased glioma and acoustic neuroma risk associated with long hours of mobile 
phone use. An epidemiological study is warranted to evaluate such a relationship in patients 
with cochlear implants.
Patients and methods: To examine whether this chronic radio frequency-electromagnetic 
field signaling is associated with an increased brain tumor risk, a population-based cohort study 
was performed examining all 2,748 patients receiving a cochlear implant in Sweden during 
the years 1989–2014. In all, 3,169 surgeries were performed in the total cohort. The expected 
occurrence of glioma, meningioma, and acoustic neuroma in the patient cohort was calculated 
using specific national incidence rates in the Swedish population.
Results: Four patients were diagnosed with a brain tumor during follow-up, three of them having 
meningioma compared with 0.95 expected (standardized incidence ratio =3.16, 95% CI 0.65–
9.24), and one had glioma compared with 1.34 expected (standardized incidence ratio =0.75, 
95% CI 0.02–4.15). No case of acoustic neuroma was observed compared with 0.09 expected.
Conclusion: In this study, we did not find support for concerns raised in a previous case report 
regarding a potentially higher risk of glioma. The number of brain tumors observed was well 
within the numbers expected from national incidence figures. Although this was a relatively 
small cohort with a limited follow-up time, it is the largest epidemiological study to date to 
address this concern.
Keywords: cochlear implants, glioblastoma, neural tumor, non-ionizing radiation, radio 
frequency-electromagnetic radiation
Introduction
A cochlear implant is an electric device that turns sound into electrical impulses. 
It has revolutionized the treatment of severe-to-profound deafness and remains the 
most successful neural prosthesis in the world, with more than 500,000 recipients 
implanted. It consists of an external part, the sound processor, and an internal implant, 
the receiver-stimulator, and the electrode array. Sound is sent through the skin as a 
frequency modulation signal to the implant by an antenna behind the ear. The coil of 
the implant picks up the signal and converts it into electrical impulses, and these are 
distributed to the cochlea corresponding to sound frequencies. Cochlear implants do 
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not restore hearing to normal but allow people that are deaf 
or with very profound hearing loss to perceive speech and 
other sounds with good results.
Cochlear implants have a long history of safety, with the 
most significant neurological side effect being bacterial men-
ingitis, although this is rare. However, it has been suggested 
that radio frequency electromagnetic fields (RF-EMFs) 
generated by mobile phones and wireless devices may be 
carcinogenic, based on epidemiological evidence on glioma 
and acoustic neuroma.1 However, the evidence is not conclu-
sive.2 Some epidemiological studies suggest that effects are 
confined to persons with many hours of mobile phone use,3,4 
whereas others have not been able to confirm this.5
We have recently reported on two cases of glioblastoma 
in geographically unrelated patients, one from Sweden and 
the other from the USA, who had long-standing cochlear 
implants.6 Extrapolating from the discussions regarding 
mobile phone use, the two cases raised concerns that long-
term exposure to low levels of RF-EMF emanating from the 
transcutaneous link of the cochlear implant could increase the 
risk of neurological tumors in patients with cochlear implants.
The risk of life-threatening side effects of a medical pro-
cedure, no matter how rare, should always be discussed with 
a patient before they undergo that procedure. This population-
based cohort study was designed to assess if patients that had 
undergone cochlear implantation had an increased risk of 
neural tumors at a population level. This would allow practi-
tioners to comprehensively discuss and assess the possibility 
of an increased risk of tumors postoperatively for patients 
about to undergo implantation.
Patients and methods
The study is based on the Swedish population and health 
data registers, and the unique personal identification num-
ber assigned to all Swedish residents. Records of cochlear 
implant surgeries were extracted from the National Patient 
Register for in-patient care between 1989 and 2014. The 
Classification of Surgical Procedures used by the Swedish 
National Board of Health and Welfare was the basis for iden-
tification, with the code 2058 during the years 1989–1996 
and DFE00 during 1997–2014. Cochlear implant patients 
were followed in the Swedish Cancer Register 1990–2015 
from 1 year after their first implant surgery, to account for a 
minimal induction and latency period. They were censored 
at the date of the first diagnosis of glioma, meningioma, or 
acoustic neuroma; date of death; date of first emigration after 
their first cochlear implant surgery; or at the end of follow-up 
on 31 December 2015. Eligible cases were first occurrence of 
glioma, meningioma, or acoustic neuroma during the follow-
up period. Tumors were classified according to definitions 
used in the Swedish Cancer Register: ICD-7 and WHO/
HS/CANC/24.1 prior to 1993; meningioma (ICD-7: 193.0 
with histology codes 461, 466), glioma (193.0, 475–476, 
485–486), and acoustic neuroma (193.0, 451, 456), and 
after 1992, the tumors were classified according to ICD-
O/2; meningioma (ICD-O/2: C70.0 with histology codes 
9530–9539), glioma (C71, 9380–9481, 9505), and acoustic 
neuroma (C72.4, 9560.0, 9560.3). The study was approved 
by the regional ethical review board in Stockholm, Sweden. 
Non-identifiable data from national health data registers were 
made available to the research team by the National Board 
of Health and Welfare, after assessment of patient confiden-
tiality and removal of all personal identifiers. No individual 
medical records were accessed during this study.
Statistical analysis
The expected number of glioma, meningioma, and acoustic 
neuroma cases in the cochlear implant cohort and standard-
ized incidence ratios (SIR) for these tumors were calculated 
using sex, age (10-year categories), and calendar year (in 
5-year categories)-specific national incidence rates in the 
Swedish population as comparison. The expected number 
of tumors, point estimates, and CIs of SIR were calculated 
using command for indirect standardization in STATA 14 
(StataCorp LP, College Station, TX, USA).
Results
According to the register, 3,169 cochlear implant opera-
tions were performed on 2,748 patients during this period; 
14.3% (395) of patients had surgery during more than one 
admission. This included sequential bilateral implantation 
or revision surgeries, where 23 patients had three or more 
surgeries during this period. The patients were born between 
1912 and 2014 and had had surgery at ages between less than 
1 year and 89 years, 55% were females. Twenty-one percent 
of the patients had their first cochlear implant surgery before 
5 years of age (Table 1).
We required tumors to be diagnosed >1 year after implant 
surgery to be considered as radiation induced. Seventeen 
patients were excluded from the study because they had been 
diagnosed with a brain tumor prior to their first cochlear 
implant surgery (between 3 months and 42 years earlier). All 
cochlear implant recipients undergo temporal bone imaging 
as a part of their preoperative investigations so these were 
not necessarily symptomatic. Eight of these patients were 
diagnosed with meningioma, two with glioma, and eight 
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 2
2-
M
ar
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1403
Cochlear implants and brain tumor epidemiology
with acoustic neuroma (one patient was diagnosed with both 
glioma and meningioma). One patient was diagnosed with 
acoustic neuroma on the same day as the cochlear implant 
operation and one patient was diagnosed with glioma 9 
months after surgery. These two patients were also excluded. 
An additional 15 patients were censored within 1 year of 
operation and were also subsequently excluded from analysis. 
Twelve of these patients had died and three had emigrated 
within 1 year of surgery. The remaining 2,714 cochlear 
implant patients were eligible to be included in the study 
(Table 1). Side of the tumor as compared to the cochlear 
implant was not considered.
The cochlear implant cohort generated in total 17,129 
person-years during the follow-up period. The mean follow-
up time of all patients was 6.3 years (median 5.1 years, 25th 
percentile 2.3, 75th percentile 8.7). Of the eligible patients, 
four were diagnosed with a brain tumor during this time, 
between 3 and 17 years after their first cochlear implant 
surgery (2.7, 3.0, 4.0, and 17.3 years). Three of these tumors 
were meningioma compared with 0.95 expected (SIR =3.16, 
95% CI 0.65–9.24), and one was a glioma compared with 
1.34 expected (SIR =0.75, 95% CI 0.02–4.15). No case of 
acoustic neuroma was observed compared with 0.09 expected.
Discussion
Contrary to the concerns raised by our recently published 
case report,6 we did not find an increased risk of malignant 
glioma, meningioma, or schwannoma in our cohort of 
patients with cochlear implants. The RF-EMFs generated 
by a cochlear implant are thus unlikely to induce tumors. 
Large epidemiological studies have failed to show a con-
sistent increased risk of brain tumors in persons exposed to 
Table 1 number of patients receiving a cochlear implant in 1989–2014 and eligible for follow-up by year and age at surgery (n=2,714)
Number of patients Person-years Tumors
Males Females Males Females Meningioma Glioma AN
Time period
1989–1994 43 51 54 60
1995–1999 104 96 317 381
2000–2004 138 154 850 879
2005–2009 378 481 1,817 2,077 2
2010–2015 566 703 4,789 5,905 1 1
Age (years) At surgery During follow-up
0–4 287 276 443 426
5–14 91 95 1,638 1,621
15–29 37 77 785 867
30–59 299 443 1,613 2,375 2 1
60+ 515 594 3,347 4,014 1
Notes: Person-years at risk during follow-up 1990–2015 by calendar year and attained age. number of brain tumors diagnosed during the follow-up period.
Abbreviation: an, acoustic neuroma.
RF-EMF.3,4 Some results indicated a potential effect associ-
ated with a large number of cumulative hours of phone use, 
although biases and errors could not be excluded as alterna-
tive explanations.3,4 A cochlear implant generates weaker RF-
EMF compared with mobile phones (20–40 mW vs 2 W) and 
operates at different frequencies (the majority of implants in 
Sweden use 5 or 12 MHz compared with 900–5,800 MHz 
for mobile phones).7 However, the maximum effect of 2 W 
from a mobile phone is for the second-generation phones 
(Global System for Mobile communications [GSM] 900 
MHz) when operating at maximum power. Adaptive power 
control makes the phone downregulate the output power to 
the lowest level possible in order to maintain communication, 
and reduces the emitted power by a factor of up to 1,000 for 
GSM phones and about 100,000,000 for Universal Mobile 
Telecommunications System (UMTS) phones. This gives an 
average reduction of 50% for GSM phones, and about two 
orders of magnitude further reduction for UMTS phones.2 In 
addition, GSM phones use Time Division Multiple Access, 
which means that the phone transmits only at regular inter-
vals, ie 12% of the time. Furthermore, discontinuous trans-
mission during voice calls gives a further reduction of the 
emitted power by an average of 30%.2 This means that the 
average emitted power during mobile phone use is 88 mW 
from a GSM 900 MHz phone and 44 mW from a GSM 1800 
MHz phone, whereas from a UMTS phone average emit-
ted power is considerably lower. Thus, the exposure levels 
generated by a cochlear implant may be of the same order 
of magnitude as from a mobile phone. In addition, it could 
be argued that over time exposure from a cochlear implant 
will become significant as most cochlear implant users will 
use their implant constantly around 16 hours per day.
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The observed incidence of brain tumors in the cochlear 
implant cohort was well within the numbers expected, con-
sidering random variation, as reflected by the 95% CI. The 
number of cochlear implant patients is small and the follow-up 
relatively short. We cannot rule out that a more highly powered 
study would find weak associations between exposure and 
tumor incidence. Still, the only patient with a glioblastoma 
among the cochlear implant patients in Sweden was our one 
Swedish index case in the case report (the other was from 
the USA)6 and the absence of additional patients is indicative 
of low risk. Various risk factors have been associated with 
glioma,8 but cochlear implants were only suggested in our 
previous report of two cases of glioblastoma after long-term 
cochlear implantation.6 In these cases, the anatomical relation 
to the implant antennas was compelling, but two patients are 
a very small proportion of the more than 500,000 cochlear 
implant recipients around the world. Furthermore, our present 
findings were based on the comprehensive population-based 
Swedish registers, ensuring complete follow-up, which is 
a strength. A more relevant objection could be that longer 
follow-up is necessary to account for tumor latency. Tumor 
latencies after ionizing radiation exposure are >5–10 years.9–11 
For nonionizing radiation, there is no known biological 
mechanism for a potential carcinogenic effect, and the tumor 
latency is unknown.2–4 Studies on mobile phone use have 
reported on various latencies with no consistent pattern of 
results.2–4 The latency of tumors induced by ionizing radia-
tion is at least greater than 4 years,10,11 whereas the latency 
of tumors potentially induced from nonionizing radiation is 
unknown. Therefore, we excluded tumors detected before or 
during application of cochlear implants and tumors detected 
less than 1 year after surgery, as it was judged that tumors 
with such short latency could not have been caused by the 
exposure from the cochlear implant. This is consistent with the 
1-year latency applied in studies of mobile phone use.2–4 This 
conservative cutoff for latency is defendable allowing false 
positive rather than false-negative observations of radiation 
induced tumors, where we considered this to be of primary 
importance in the present setting. In addition, the Interphone 
study found the strongest risk estimate for glioma among 
persons with many hours of mobile phone use accrued with 
short latency (<5 years).3 Thus, the exposure from a cochlear 
implant in our study may be of a comparable intensity and 
duration. Our findings do not confirm the results in the Inter-
phone study for glioma. Studies of meningioma in relation to 
mobile phone use have not indicated increased risks.1
A cochlear implant consists of two parts, an external sound 
processor with microphones and antenna and an internal 
receiver-stimulator that is beneath the skin and imbedded in 
the skull. Communication between these two parts is depen-
dent on RF signaling that in turn generates an RF-EMF. There 
is significant debate in the literature around whether RF-EMF 
can result in an increased incidence of neurological tumors. 
A few case–control studies with self-reported histories of 
mobile phone use have reported considerable risk increases 
among mobile phone users primarily for glioma and acoustic 
neuroma, and also after short exposure latencies (reviewed 
by Scientific Committee on Emerging and Newly Identified 
Health Risks [SCENIHR]).2 However, cohort studies with 
independently collected exposure information have not found 
any increased risks,12–14 and incidence trend studies have not 
found changes in the brain tumor incidence that would corre-
spond to an effect of RF exposure from mobile phone use.15,16 
On the contrary, brain tumor incidence trends have been stable 
since the introduction of handheld mobile phones. Taken 
together, our negative findings in this study agree with a large 
body of epidemiological literature on RF-EMF exposure.2
Conclusion
Our study shows no relationship between cochlear implant use 
and the incidence of glioma or any other neural tumor. These 
epidemiological findings do not support an increased risk of 
neurological tumors in patients with cochlear implants, and, 
therefore a risk of malignancy need not be part of patient infor-
mation or informed consent before cochlear implantation.
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